Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
PLoS One ; 15(9): e0238999, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32915889

RESUMEN

Aberrant expression of the transcription factor ERG is a key driving event in approximately one-half of all of prostate cancers. Lacking an enzymatic pocket and mainly disordered, the structure of ERG is difficult to exploit for therapeutic design. We recently identified EWS as a specific interacting partner of ERG that is required for oncogenic function. In this study, we aimed to target this specific protein-protein interaction with small molecules. A high-throughput screening (HTS) strategy was implemented to identify potential protein-protein interaction inhibitors. Secondary assays verified the function of several hit compounds, and one lead compound inhibited ERG-mediated phenotypes in prostate cells. This is the first study aimed at targeting the ERG-EWS protein-protein interaction for the development of a small molecule-based prostate cancer therapy.


Asunto(s)
Ensayos Analíticos de Alto Rendimiento/métodos , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/metabolismo , Proteína EWS de Unión a ARN/antagonistas & inhibidores , Línea Celular Tumoral , Ensayos de Selección de Medicamentos Antitumorales/métodos , Estudios de Factibilidad , Humanos , Masculino , Neoplasias de la Próstata/genética , Dominios y Motivos de Interacción de Proteínas/efectos de los fármacos , Proteína EWS de Unión a ARN/genética , Proteína EWS de Unión a ARN/metabolismo , Proteínas Recombinantes/efectos de los fármacos , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Bibliotecas de Moléculas Pequeñas , Regulador Transcripcional ERG/antagonistas & inhibidores , Regulador Transcripcional ERG/genética , Regulador Transcripcional ERG/metabolismo
2.
Nurs Adm Q ; 42(2): 143-149, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29494449

RESUMEN

The National Institute of Nursing Research (NINR) has a Friends group. This organization, the Friends of the National Institute of Nursing Research (FNINR), has been in place for over 20 years. It serves as a bold voice to communicate the impact of NINR's work to elevate nursing science, improve lives, while advancing the nation's health. FNINR's mission is to provide resources to support nursing research and advance the mission of the NINR. In 2013, the FNINR led the creation, development, and growth of an Ambassadors Program. The Ambassador Program is a group of committed individuals who are willing to serve as advocates of the NINR. Chosen through an application process reviewed by the FNINR Advocacy Committee of the FNINR Board, these selected Ambassadors work to influence Congress and advocate for the goals and visions of the NINR. This designation was initially limited to an elite group, and peer networking and communication was built into the program. The goal of the FNINR Ambassadors Program is to extend the reach of advocacy efforts for improving the funding and knowledge about the NINR. Thirty ambassadors across the country are working to expand knowledge and educate stakeholders about the impact of nursing science on the health of the country. This article describes the process the FNINR conducted to develop the Ambassadors Program, and the outcomes associated with this program.


Asunto(s)
Defensa del Consumidor , Investigación en Enfermería , Historia del Siglo XX , Humanos , Investigación en Enfermería/tendencias , Sociedades de Enfermería/historia , Sociedades de Enfermería/organización & administración , Recursos Humanos
3.
Int J Toxicol ; 34(4): 318-24, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26111539

RESUMEN

C-peptide is formed in the biosynthesis of insulin and is therefore deficient in patients with type 1 diabetes mellitus. A pegylated form of human synthetic C-peptide (CBX129801) has been developed to extend the half-life of the native peptide and is undergoing clinical investigation as replacement therapy to treat diabetic peripheral neuropathy. This monkey study was conducted to evaluate the toxicity of CBX129801 with weekly subcutaneous dosing for 39 weeks at dose levels of 0 (vehicle), 0.4, 1.33, and 4.0 mg/kg/wk. No systemic adverse effects were observed at any dose with maximal CBX129801 plasma concentrations of 735 to 1050 nmol/L during the dosing period (physiological range is 1-3 nmol/L). CBX129801-related effects were limited to minimal macrophagic vacuolization at the injection sites and in the associated draining (axillary) lymph nodes; these local effects largely resolved by the end of a 7-week recovery period. No systemic macrophagic vacuolization was observed. Additionally, there was no histological evidence for plaque formation in the major arteries of these nondiabetic animals.


Asunto(s)
Péptido C/farmacocinética , Péptido C/toxicidad , Polietilenglicoles/farmacocinética , Polietilenglicoles/toxicidad , Animales , Péptido C/administración & dosificación , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Neuropatías Diabéticas/tratamiento farmacológico , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Femenino , Semivida , Humanos , Inyecciones Subcutáneas , Macaca fascicularis , Masculino , Nivel sin Efectos Adversos Observados , Placa Aterosclerótica/sangre , Placa Aterosclerótica/inducido químicamente , Polietilenglicoles/administración & dosificación , Toxicocinética
4.
Brain Res ; 1473: 44-54, 2012 Sep 14.
Artículo en Inglés | MEDLINE | ID: mdl-22842079

RESUMEN

The ability of adult injured postganglionic axons to reinnervate cerebrovascular targets is unknown, yet these axons can influence cerebral blood flow, particularly during REM sleep. The objective of the present study was to assess quantitatively the sympathetic reinnervation of vascular as well as non-vascular targets following bilateral axotomy of the superior cervical ganglion (SCG) at short term (1 day, 7 day) and long term (8 weeks, 12 weeks) survival time points. The sympathetic innervation of representative extracerebral blood vessels [internal carotid artery (ICA), basilar artery (BA), middle cerebral artery (MCA)], the submandibular gland (SMG), and pineal gland was quantified following injury using an antibody to tyrosine hydroxylase (TH). Changes in TH innervation were related to TH protein content in the SCG. At 7 day following bilateral SCG axotomy, all targets were significantly depleted of TH innervation, and the exact site on the BA where SCG input was lost could be discerned. Complete sympathetic reinnervation of the ICA was observed at long term survival times, yet TH innervation of other vascular targets showed significant decreases even at 12 weeks following axotomy. The SMG was fully reinnervated by 12 weeks, yet TH innervation of the pineal gland remained significantly decreased. TH protein in the SCG was significantly decreased at both short term and long term time points and showed little evidence of recovery. Our data demonstrate a slow reinnervation of most vascular targets following axotomy of the SCG with only minimal recovery of TH protein in the SCG at 12 weeks following injury.


Asunto(s)
Regeneración Nerviosa/fisiología , Ganglio Cervical Superior/fisiología , Animales , Axotomía , Arteria Basilar/inervación , Arteria Carótida Interna/inervación , Femenino , Arteria Cerebral Media/inervación , Glándula Pineal/inervación , Ratas , Ratas Sprague-Dawley , Glándula Submandibular/inervación , Ganglio Cervical Superior/lesiones
5.
Cloning Stem Cells ; 11(2): 259-67, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19522673

RESUMEN

Research into the behavior, efficacy, and biosafety of stem cells with a view to clinical transplantation requires the development of noninvasive methods for in vivo imaging of cells transplanted into animal models. This is particularly relevant for human embryonic stem cells (hESCs), because transplantation of undifferentiated hESCs leads to tumor formation. The present study aimed to monitor hESCs in real time when injected in vivo. hESCs were stably transfected to express luciferase, and luciferase expression was clearly detected in the undifferentiated and differentiated state. When transfected hESCs were injected into chick embryos, bioluminescence could be detected both ex and in ovo. In the SCID mouse model, undifferentiated hESCs were detectable after injection either into the muscle layer of the peritoneum or the kidney capsule. Tumors became detectable between days 10-30, with approximately a 3 log increase in the luminescence signal by day 75. The growth phase occurred earlier in the kidney capsule and then reached a plateau, whilst tumors in the peritoneal wall grew steadily throughout the period analysed. These results show the widespread utility of bioluminescent for in vivo imaging of hESCs in a variety of model systems for preclinical research into regenerative medicine and cancer biology.


Asunto(s)
Células Madre Embrionarias/fisiología , Mediciones Luminiscentes/métodos , Trasplante de Células Madre/métodos , Animales , Diferenciación Celular/fisiología , Embrión de Pollo , Células Madre Embrionarias/citología , Colorantes Fluorescentes/metabolismo , Humanos , Luciferasas/genética , Luciferasas/metabolismo , Ratones , Ratones SCID , Programas Informáticos , Teratoma/metabolismo , Teratoma/patología
6.
Cancer Res ; 69(5): 1792-9, 2009 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-19223548

RESUMEN

High levels of expression of the human DEK gene have been correlated with numerous human malignancies. Intracellular DEK functions have been described in vitro and include DNA supercoiling, DNA replication, RNA splicing, and transcription. We have shown that DEK also suppresses cellular senescence, apoptosis, and differentiation, thus promoting cell growth and survival in monolayer and organotypic epithelial raft models. Such functions are likely to contribute to cancer, but direct evidence to implicate DEK as an oncogene has remained elusive. Here, we show that in line with an early role in tumorigenesis, murine papilloma formation in a classical chemical carcinogenesis model was reduced in DEK knockout mice. Additionally, human papillomavirus E6/E7, hRas, and DEK cooperated in the transformation of keratinocytes in soft agar and xenograft establishment, thus also implicating DEK in tumor promotion at later stages. Finally, adenoviral DEK depletion via short hairpin RNA expression resulted in cell death in human tumor cells in vitro and in vivo, but did not significantly affect differentiated epithelial cells. Taken together, our data uncover oncogenic DEK activities as postulated from its frequent up-regulation in human malignancies, and suggest that the targeted suppression of DEK may become a strategic approach to the treatment of cancer.


Asunto(s)
Transformación Celular Neoplásica , Proteínas Cromosómicas no Histona/fisiología , Proteínas de Unión al ADN/fisiología , Neoplasias/etiología , Proteínas Oncogénicas/fisiología , Animales , Apoptosis , Línea Celular Tumoral , Proteínas Cromosómicas no Histona/genética , Femenino , Humanos , Ratones , Ratones Endogámicos C57BL , Proteínas Oncogénicas/genética , Proteínas Oncogénicas Virales/genética , Papiloma/etiología , Proteínas E7 de Papillomavirus , Proteínas de Unión a Poli-ADP-Ribosa , Proteínas Represoras/genética
7.
Am J Pathol ; 174(1): 71-81, 2009 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19036808

RESUMEN

Overexpression of the DEK gene is associated with multiple human cancers, but its specific roles as a putative oncogene are not well defined. DEK transcription was previously shown to be induced by the high-risk human papillomavirus (HPV) E7 oncogene via E2F and Rb pathways. Transient DEK overexpression was able to inhibit both senescence and apoptosis in cultured cells. In at least the latter case, this mechanism involved the destabilization of p53 and the decreased expression of p53 target genes. We show here that DEK overexpression disrupts the normal differentiation program in a manner that is independent of either p53 or cell death. DEK expression was distinctly repressed upon the differentiation of cultured primary human keratinocytes, and stable DEK overexpression caused epidermal thickening in an organotypic raft model system. The observed hyperplasia involved a delay in keratinocyte differentiation toward a more undifferentiated state, and expansion of the basal cell compartment was due to increased proliferation, but not apoptosis. These phenotypes were accompanied by elevated p63 expression in the absence of p53 destabilization. In further support of bona fide oncogenic DEK activities, we report here up-regulated DEK protein levels in both human papilloma virus-positive hyperplastic murine skin and a subset of human squamous cell carcinomas. We suggest that DEK up-regulation may contribute to carcinoma development at least in part through increased proliferation and retardation of differentiation.


Asunto(s)
Diferenciación Celular/genética , Transformación Celular Neoplásica/genética , Proteínas Cromosómicas no Histona/biosíntesis , Células Epiteliales/citología , Queratinocitos/citología , Proteínas Oncogénicas/biosíntesis , Animales , Western Blotting , Carcinoma de Células Escamosas/genética , Carcinoma de Células Escamosas/patología , Carcinoma de Células Escamosas/virología , Proliferación Celular , Transformación Celular Neoplásica/metabolismo , Transformación Celular Neoplásica/patología , Células Cultivadas , Proteínas Cromosómicas no Histona/genética , Proteínas Cromosómicas no Histona/metabolismo , Proteínas de Unión al ADN/metabolismo , Células Epiteliales/patología , Células Epiteliales/virología , Epitelio/metabolismo , Epitelio/patología , Técnica del Anticuerpo Fluorescente , Prepucio/citología , Expresión Génica , Humanos , Hiperplasia/genética , Hiperplasia/metabolismo , Hiperplasia/virología , Queratinocitos/patología , Queratinocitos/virología , Masculino , Proteínas de la Membrana/metabolismo , Ratones , Ratones Transgénicos , Proteínas Oncogénicas/genética , Proteínas Oncogénicas/metabolismo , Proteínas E7 de Papillomavirus/genética , Proteínas de Unión a Poli-ADP-Ribosa , Proto-Oncogenes Mas , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Regulación hacia Arriba
8.
J Soc Work Disabil Rehabil ; 7(3-4): 163-86, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-19064429

RESUMEN

This article describes an innovative statewide collaboration between schools of social work and public mental health departments to transform social work curriculum and address the workforce crisis in public mental health service systems. The collaborative partnership has fostered the development of a Mental Health Initiative that has developed a set of mental health competencies offered in each of the participating master's in social work (MSW) programs in California. These competencies identify critical skills and knowledge necessary to support recovery, resiliency, evidence-based practice, and psychosocial rehabilitation principles. A statewide stipend program to support final-year MSW students in their graduate study and a requirement for a year of employment payback in the public mental health system is also presented, as well as a brief discussion of the organizational and structural principles supporting the collaborative organization. Current successes, future challenges, and strategies for the partnership collaborative in their task of developing a workforce are addressed.


Asunto(s)
Educación Basada en Competencias , Conducta Cooperativa , Curriculum , Asistencia Social en Psiquiatría/educación , California , Educación de Postgrado/economía , Fuerza Laboral en Salud , Humanos , Relaciones Interprofesionales , Trastornos Mentales/rehabilitación , Asistencia Social en Psiquiatría/legislación & jurisprudencia , Estudiantes del Área de la Salud , Universidades
9.
J Nucl Med ; 48(4): 615-22, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17401100

RESUMEN

UNLABELLED: The gastrin/cholecystokinin-2 (CCK-2) receptor has been identified as a possible target for peptide receptor radionuclide imaging and therapy. Several radiolabeled peptides binding to this receptor have been explored in animal models and clinical trials but either low tumor uptake or high renal retention has been found. The aim of this study was to identify a peptide with improved tumor-to-kidney pharmacodynamics when compared with current candidates. METHODS: A small peptide-chelator library of 34 compounds based on the C-terminal sequences of CCK-8 or minigastrin was constructed. The peptides were radiolabeled with (111)In with high labeling efficiency (>90%), as determined by high-performance liquid chromatographic analysis. The labeled peptides were screened by assessing tumor and kidney uptake in pancreatic xenograft nude mouse models, including AR42J. An extensive biodistribution analysis was performed on the lead candidate from the library. RESULTS: Minigastrin analogs containing a pentaglutamate sequence showed the highest tumor uptake but very high renal retention. CCK analogs showed the lowest tumor and renal uptake. Deletion of the pentaglutamate sequence in the gastrin analogs lowered the tumor uptake by a factor of 3 but decreased the kidney uptake by a factor of 20. Insertion of histidine residues in the sequence reduced kidney uptake by a further factor of almost 2-fold. In AR42J tumor-bearing mice, the peptide with the sequence DOTA-HHEAYGWMDF-NH(2) (DOTA is tetraazacyclododecane tetraacetic acid) showed the highest tumor-to-kidney ratio of all peptides studied, with saturable uptake in target organs and low uptake by nontarget tissues other than the kidney. CONCLUSION: This peptide is a worthwhile candidate for clinical studies to determine whether it is suitable for use in peptide receptor-targeted radionuclide therapy.


Asunto(s)
Gastrinas/química , Neoplasias/tratamiento farmacológico , Receptores de Péptidos/química , Secuencia de Aminoácidos , Animales , Línea Celular Tumoral , Humanos , Riñón/metabolismo , Masculino , Ratones , Ratones Desnudos , Datos de Secuencia Molecular , Trasplante de Neoplasias , Ratas , Receptor de Colecistoquinina B/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA